6533b86cfe1ef96bd12c834b
RESEARCH PRODUCT
Central retinal artery occlusion-A new, provisional treatment approach.
Argyrios ChronopoulosArgyrios ChronopoulosJames Scott Schutzsubject
MassageRetinal Ganglion Cellsmedicine.medical_specialtybusiness.industryRetinal Artery OcclusionAnticoagulantsCherry-red spotCerebral strokemedicine.diseaseRetinal ganglionOphthalmologyFibrinolytic AgentsOphthalmologyOptic nerveMedicineCentral retinal artery occlusionHumansSmall vesselmedicine.symptombusinessStrokeAntihypertensive AgentsIntraocular PressureRetinal infarctiondescription
The retinal ganglion cells infarcted in central retinal artery occlusion (CRAO) are the somata of the optic nerve axons, part of the central nervous system. Consequently, CRAO with inner retinal infarction is a small vessel stroke, usually with the devastating consequence of severe visual loss in the affected eye. At present, there is no generally accepted, evidence-based therapy of nonarteritic CRAO in contrast to ischemic cerebral stroke that has well-accepted treatment protocols. Widely divergent and controversial therapeutic options for CRAO reflect the desperation of treating physicians and disparate conflicting studies. We examine reasons why treatment of nonarteritic CRAO remains problematic and then suggest a provisional new approach to treatment based on updated understanding of CRAO pathophysiology and analysis of current therapeutic options and their rationales.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-07-01 | Survey of ophthalmology |